 |
| RNA Therapeutics: What Works, What Is Next, and What Still Blocks the Field |
RNA medicines are now a real product class, but the next decade depends on delivery, manufacturing, and platform-aware regulation.
RNA Therapeutics in 2026: From Platform Promise to Delivery Reality
RNA-centered therapeutics have moved from a "promising
platform" story to a differentiated product class with real regulatory,
commercial, and clinical traction. The strongest proof points now sit in three clusters:
vaccines built on translatable RNA, liver-directed RNA silencing using GalNAc
conjugates or lipid nanoparticles, and antisense medicines for rare or
genetically defined disease. The last three years were especially important:
the FDA approved mRESVIA in 2024 as the first mRNA vaccine for a non-COVID
indication, the EU approved the self-amplifying RNA vaccine Kostaive in 2025
after Japan's 2023 authorization, and 2025 alone brought three new
oligonucleotide approvals in the U.S. - fitusiran, donidalorsen, and plozasiran
- signaling that RNA medicines are broadening beyond niche neurology and
transthyretin disease. At the same time, the field remains uneven: miRNA
therapeutics still have no phase III successes or approvals, CRISPR-based RNA
editing has only just entered early human testing, and circular RNA remains a
platform bet rather than a validated product class.
Analytically, the field's central challenge is no longer
whether RNA can work, but where and how reliably it can work. Delivery beyond liver
and locally accessible tissues remains the dominant bottleneck; endosomal
escape, tissue biodistribution, repeat-dose immunogenicity, chemistry-dependent
toxicity, and scalable manufacturing still constrain the jump from rare disease
to common disease. The regulatory environment is becoming more favorable,
however: FDA finalized clinical pharmacology guidance for oligonucleotide
therapeutics in 2024, issued draft nonclinical safety guidance in late 2024,
and launched a 2026 framework for individualized ultra-rare therapies; EMA in
parallel published synthetic oligonucleotide manufacturing guidance in 2024 and
mRNA-vaccine quality guidance in 2025. In practice, this means the next wave of
winners will likely be companies that treat delivery, analytics, and regulatory
design as an integrated platform rather than as separate workstreams.
For an industry audience, the biggest opportunity is clear:
RNA offers the fastest route from target validation to drug candidate for many
classes of disease biology, especially where the target is genetically defined,
intracellular, or "undruggable" by classical small molecules and
antibodies. But the platform is fragmenting. There is no single "RNA
market"; instead there are several operating models: chronic liver-directed
RNAi for prevalent cardiometabolic disease, personalized or semi-personalized
cancer vaccination, splice modulation by ASOs or small molecules, locally
delivered ocular and CNS medicines, and now an emerging frontier of transient
RNA editing. The most credible near-term strategy is to build on validated
chemistries and delivery routes while selectively investing in extrahepatic
targeting, AI-guided sequence and nanoparticle design, and manufacturing
systems that can handle both precision and scale.
RNA Modalities And Mechanisms
"RNA-centered therapeutics" is best understood as
two related families: medicines made of RNA or oligonucleotides, and medicines
that target RNA as a substrate. Within that umbrella, mechanism matters more
than modality labels. mRNA and circRNA deliver coding information for protein
production; siRNA exploits RNA interference through Ago2/RISC-mediated
cleavage; antisense oligonucleotides can trigger RNase H1 degradation,
sterically block translation, or switch splicing; miRNA therapeutics either
replace lost regulatory microRNAs or inhibit pathogenic ones; aptamers use
folded nucleic acids as ligands; RNA-targeting small molecules bind structured
RNA or splice-regulatory motifs; and CRISPR/Cas13-style RNA editors offer
transient, programmable RNA knockdown or base editing without permanent DNA
changes. The platform lesson from the last decade is that "RNA" is
not a single drug class but a family of pharmacologies, chemistries, and
delivery logics.
The strategic takeaway from this comparison is that
mechanism-specific fit is decisive. If the disease biology is
hepatocyte-centric and chronic, siRNA or GalNAc-ASO often has the best
benefit-risk and manufacturing logic. If rapid protein expression is needed,
mRNA or saRNA is attractive, particularly in vaccines and oncology. If the
therapeutic goal is splice correction, ASOs and RNA-binding small molecules
remain the leaders. And if transient reversibility matters - a compelling
argument in retina or other tissues where permanent genomic editing may be too
risky - RNA editing is conceptually powerful but still clinically immature.
Breakthroughs And Clinical Translation
A helpful way to read the current landscape is by asking
which modalities have crossed the "platform credibility" threshold.
By mid-2026, that threshold has clearly been crossed by mRNA vaccines, multiple
ASO subclasses, and liver-directed siRNA. The more recent approvals matter
because they show breadth expansion: from COVID to RSV and saRNA vaccines; from
hATTR and rare liver diseases to hypercholesterolemia, hemophilia, familial
chylomicronemia syndrome, and hereditary angioedema; and from gene suppression
alone to splice modulation and biomarker-driven accelerated approval. By
contrast, the modalities still waiting for a definitive translation signal are
miRNA, circRNA, and CRISPR-based RNA editing.
Two breakthrough patterns stand out. First, liver delivery
is no longer just a rare-disease story. Inclisiran moved RNAi into high-volume
cardiovascular prevention; plozasiran and olezarsen positioned RNA medicines
against severe triglyceride disorders; and fitusiran extended RNAi toward
hematology with a mechanism defined by antithrombin silencing rather than
target replacement. Second, regulators have become comfortable with mechanism-matched
evidence packages, even when those packages are unconventional: tofersen's
accelerated approval based on plasma neurofilament reduction is the clearest
recent case.
The unresolved story is therapeutic mRNA outside vaccines.
The Merck-Moderna melanoma program remains the most advanced signal: five-year
Phase 2b KEYNOTE-942 data presented on June 1, 2026 showed sustained
recurrence-free and distant metastasis-free survival improvements for
intismeran autogene (mRNA-4157/V940) plus pembrolizumab, but the product
remains investigational and unapproved. Meanwhile, recent corporate behavior
suggests that big pharma believes the next upside may come from
"RNA-plus-delivery" platform combinations rather than naked modality
bets - a logic visible in Lilly's 2026 move for Orna's circular RNA plus LNP
platform and Novo Nordisk's 2024 acquisition of Cardior's cardiovascular RNA
assets.
Core Technical Bottlenecks
Delivery remains the field's most consequential bottleneck.
The liver is the best-served organ because both GalNAc conjugation and many LNP
compositions naturally favor hepatocyte uptake. GalNAc conjugates exploit the
asialoglycoprotein receptor and have enabled the durable, infrequent
subcutaneous dosing seen with agents such as inclisiran and plozasiran. Outside
the liver, however, the problem becomes much harder: serum protein binding,
nanoparticle corona formation, endothelial barriers, endosomal escape, and
cellular heterogeneity all degrade effective delivery. Recent reviews continue
to describe extrahepatic delivery as the major translational limitation for
oligonucleotides and LNP-RNA systems.
Stability and immunogenicity cut both ways. For therapeutic
RNAs, chemical modification is usually essential, not optional.
Phosphorothioate backbones, 2'-O-methyl, 2'-MOE, LNA, and related modifications
improve nuclease resistance, protein binding, and potency for oligonucleotides;
N1-methylpseudouridine, optimized caps, and poly(A) architecture improved
translatable RNA performance and were central to the COVID vaccine era. But
each gain brings tradeoffs: backbone chemistry can drive protein-binding
toxicities, PEG-bearing formulations raise complement and anti-PEG questions,
and innate immune activation must be minimized for chronic therapeutics while being
harnessed, not erased, in vaccines. FDA's 2024 clinical pharmacology guidance
explicitly treats immunogenicity risk assessment as a core development task for
oligonucleotide therapeutics, and FDA in 2025 required updated
myocarditis/pericarditis warnings for mRNA COVID-19 vaccines - a reminder that
platform safety liabilities can evolve after launch.
Specificity is also more complicated than "Watson-Crick
matching" suggests. siRNA can produce seed-mediated off-target repression;
ASOs can create hybridization-dependent and hybridization-independent
toxicities; splice correction can reveal cryptic or tissue-specific biology;
and miRNA therapies face the hardest problem of all because one miRNA often
regulates many transcripts across multiple tissues. This is a major reason the
miRNA field has lagged: recent analyses still conclude that the space has
generated intriguing biology but no phase III winners or marketed products. By
contrast, tofersen shows that when genetic causality is unusually strong and biomarkers
are mechanistically coherent, regulators may tolerate residual uncertainty.
Manufacturing is now a strategic differentiator. Traditional
solid-phase oligonucleotide synthesis works for rare diseases, but
broad-population RNA medicines require cleaner impurity control, lower solvent
intensity, better analytics, and eventually higher-throughput or alternative
synthesis routes. EMA's 2024 oligonucleotide guideline explicitly addresses
characterization, specifications, analytical control, conjugation, and product
development. On the mRNA side, the key CMC pain points are template quality, in
vitro transcription consistency, capping, dsRNA impurities, purification,
formulation, sterile fill-finish, and comparability when platforms are updated.
The fact that EMA issued a dedicated 2025 guideline on mRNA-vaccine quality is
itself evidence that RNA CMC has become specialized enough to require
modality-specific regulation.
CNS and tissue targeting remain the hardest frontier. The
clinical successes in CNS RNA medicine - from nusinersen to tofersen - relied
on local intrathecal delivery, not systemic blood-brain barrier penetration.
Reviews in 2025 continue to emphasize receptor-mediated transport, peptide
targeting, focused ultrasound, and locally delivered nanoparticles as the most
credible routes to broader CNS translation. Retina, lung, muscle, and immune
cells are all active targets; but compared with hepatocytes, none yet has a
universally accepted delivery standard equivalent to GalNAc. That imbalance
explains why so much platform innovation is now aimed at barcoded in vivo
screening, organ-specific lipid design, peptides, antibody-oligo conjugates,
and hybrid local/systemic strategies.
Enabling Technologies And Innovation Engines
The enabling-technology story is no longer just "LNPs
got better." It is an ecosystem of chemistry, screening, computation, and
manufacturing.
Novel delivery systems
Extrahepatic LNP engineering is the clearest active
frontier. High-impact 2024-2025 work used barcoded in vivo screens to identify
lipid formulations with lung and immune-cell tropism, while a 2025 Nature
Biotechnology paper described AI-guided LNP design for pulmonary gene therapy. More
broadly, recent reviews of LNP fate emphasize that composition alone is not
enough: corona biology, endosomal escape, particle morphology, and tissue
microenvironment all influence performance. If first-generation RNA delivery
was "make a stable particle," second-generation delivery is
"engineer the whole in vivo journey."
Chemical modification and scaffold innovation
For oligonucleotides, the foundational playbook remains
backbone and sugar modification plus targeted conjugation. For mRNA and saRNA,
the differentiators are now optimized UTRs, codon architecture, caps, modified
nucleosides, dsRNA impurity control, and formulations matched to route and
indication. Circular RNA adds another engineering layer: ribosome entry,
circularization chemistry, purity, and translational control. Recent big-pharma
interest in Orna suggests that industry increasingly values circRNA not just
for longer expression, but for the possibility of combining durable translation
with in vivo cell engineering.
In vivo selection, next-generation SELEX, and high-throughput biology
RNA discovery is becoming more empirical and more
multiplexed. Discovery platforms for RNA therapeutics now pair computational
design with ex vivo functional assays, organoid systems, barcoded in vivo screening,
and improved aptamer-selection workflows. In aptamers specifically, advances in
SELEX and post-selection modification aim to solve historical liabilities in
affinity, degradation, and tissue specificity. The common industry pattern is
clear: library-scale experimentation is replacing the older, serial
"candidate-by-candidate" optimization model.
AI and ML design
AI is becoming useful precisely where the design space is
combinatorial: RNA sequence design, secondary-structure optimization, codon
choice, untranslated regions, and nanoparticle formulation. The most credible
near-term use case is not fully autonomous drug design, but constrained
optimization - using ML to triage huge sequence or lipid spaces before wet-lab
selection. The strongest evidence so far is in delivery-system design and
screening acceleration, not in replacing biology-led target selection.
Manufacturing innovation
RNA manufacturing is moving toward three priorities:
higher-fidelity synthesis, better real-time analytics, and more scalable
process architectures. End-to-end continuous mRNA production was demonstrated
earlier, but recent work is making the workflow more industrially relevant
through in-process analytics and platform-scale control. On the oligonucleotide
side, enzymatic synthesis is becoming a serious long-term alternative to
conventional phosphoramidite chemistry, including a 2025 Nature Biotechnology
report of template-independent enzymatic RNA oligo synthesis. These advances
matter commercially because RNA's next growth phase depends on moving from
kilogram-scale rare-disease supply to much larger and more sustainable
production systems.
Business, Policy, And Access
The most successful business models in RNA therapeutics now
share one principle: monetize the platform by narrowing the technical risk.
Merck and Moderna's V940 collaboration is a classic
shared-development/shared-profit model, with the companies publicly stating
equal cost and profit sharing. Novo Nordisk's acquisition of Cardior for up to
EUR1.025 billion shows the value placed on mechanistically differentiated
extrahepatic RNA assets in cardiovascular disease. Lilly's February 2026
agreement to acquire Orna - reported by Lilly as an acquisition to advance cell
therapies through circular RNA plus LNPs, and by Reuters as worth up to $2.4
billion - reflects a second pattern: big pharma is willing to pay for enabling
platforms even before late-stage proof, if the platform plausibly opens a new
therapeutic category such as in vivo CAR-T.
A second business model is regional commercialization and
specialization. Ionis has repeatedly used this model - for example in
eplontersen with AstraZeneca and in Asia-Pacific expansion for donidalorsen
with Otsuka - to reduce launch burden while preserving platform value. This model
fits RNA especially well because disease-area expertise, route-specific
clinical operations, and reimbursement strategy differ sharply across
neurology, cardiometabolic disease, rare immunology, and vaccines. RNA
companies that try to be both platform innovators and fully integrated
commercial organizations often end up overextended.
Policy is becoming more important, not less. The FDA's
2024-2026 actions - final oligonucleotide clinical pharmacology guidance, draft
nonclinical ONT guidance, platform technology designation, and a framework for
individualized ultra-rare therapies - collectively indicate a more
platform-aware regulatory posture. EMA's 2024 synthetic oligonucleotide
manufacturing guideline and 2025 mRNA-vaccine quality guideline show the same
shift in Europe. These are not bureaucratic footnotes: for RNA developers,
regulatory alignment on CMC, biodistribution, biomarkers, and platform
comparability is now a source of competitive advantage.
Korea is relevant here as both a policy test case and a
manufacturing node. In May 2025, the Korean government announced a four-year
mRNA vaccine self-sufficiency project supporting development from nonclinical
work through phase III. The Ministry of Health and Welfare's 2025 Korean ARPA-H
call also included a personalized cancer-vaccine optimization platform. In
parallel, WHO and Korean partners continued to build the Republic of Korea's
role as a global biomanufacturing training hub for vaccine and biologics
capacity. For RNA therapeutics, this combination - domestic platform ambition
plus global training and manufacturing policy - is exactly the kind of
ecosystem strategy that can matter as much as any single asset.
Safety, ethics, and access remain structural issues. RNA
medicines often target rare diseases with high per-patient prices and complex
lifelong dosing; outside vaccines, global manufacturing remains geographically
concentrated; and individualized approaches raise fairness questions that
classical blockbuster models do not. FDA's 2022 guidance for individualized
investigational ASOs and its 2026 individualized-therapy framework are
important because they implicitly recognize these tensions: how much evidence
is enough for a mutation-specific or N-of-1 therapy, and who will pay for it?
Vaccine history also matters. WHO's mRNA technology-transfer program and the
lessons of COVAX underscore that rapid RNA innovation does not automatically
produce equitable access unless manufacturing know-how, training, and
procurement mechanisms are deliberately distributed.
Actionable Recommendations And Outlook
For the short term, the best opportunities are highly
target-validated, route-matched programs. That means liver-directed
cardiometabolic RNAi, ASOs or small molecules for splicing disorders, and
improved local-delivery programs in eye and CNS. Companies should prioritize
mechanisms with measurable biomarkers, accepted clinical endpoints, and a
delivery route that already has regulatory precedent. In parallel, teams should
build CMC and bioanalytical sophistication early - especially impurity
profiling, biodistribution strategy, and comparability planning - because those
are now frequent rate-limiting steps, not back-end chores.
For the medium term, the field should focus on extrahepatic
delivery and selective platform generalization. The most important technical
investments are organ- and cell-selective LNPs, conjugates for
muscle/immune/CNS targeting, endosomal-escape engineering, and barcoded in vivo
discovery systems tied to AI-guided optimization. Therapeutic mRNA beyond
vaccines is likely to succeed first where manufacturing speed and
personalization matter most - oncology, immunotherapy, and possibly select
protein-replacement settings with local or repeatable dosing. Regulators are
signaling openness to platform approaches, so companies should seek development
programs that let them reuse validated chemistry, analytics, and formulation
knowledge across multiple assets.
For the long term, the highest upside sits in transient cell
engineering and programmable RNA repair. CRISPR-based RNA editing could become
attractive in settings where reversibility is a feature, not a bug, but only if
delivery becomes substantially better and long-term safety packages become
clearer. Circular RNA also remains a meaningful long-term opportunity,
especially if it proves superior for durable but non-permanent protein
expression in immune reprogramming or regenerative contexts. The caution is
that both areas are still pre-validation. Strategic capital should therefore
favor platform options and milestone-based partnerships rather than premature
commercialization assumptions.
The most realistic future outlook is therefore selective
expansion, not universal platform dominance. RNA therapeutics will likely keep
winning first where biology is genetically sharp, tissue exposure is solvable,
and biomarkers allow rapid iteration. That set already includes vaccines, liver
disease, some neurologic disease, and parts of immunology and hematology. The
next decade's real breakthrough will be the first broadly reproducible
extrahepatic delivery platform. If that arrives, RNA therapeutics could move
from a successful specialty class to a central pillar of mainstream drug
development. If it does not, the field will still grow - but as several highly
successful niches rather than one all-conquering modality.
Open Questions And Limitations
This review prioritizes official and primary sources, but
several emerging areas remain fluid as of 3 June 2026. Therapeutic mRNA outside
vaccines is still late-stage rather than approved in the sources reviewed here;
miRNA and circRNA lack major-market approvals; and CRISPR-based RNA editing is
only just entering early human trials. Some company pipeline claims -
especially in preclinical circRNA and extrahepatic delivery - remain ahead of
peer-reviewed clinical validation and should be treated as directional rather
than settled.
References
Regulatory guidance and product approvals
Clinical Pharmacology Considerations for the Development of
Oligonucleotide Therapeutics. U.S. FDA, 2024.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-development-oligonucleotide-therapeutics
Nonclinical Safety Assessment of Oligonucleotide-Based
Therapeutics. U.S. FDA, 2024 draft.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-assessment-oligonucleotide-based-therapeutics
Considerations for the use of the Plausible Mechanism
Framework to Develop Individualized Therapies that Target Specific Genetic
Conditions with Known Biological Cause. U.S. FDA, 2026 draft.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific
Development and manufacture of oligonucleotides - Scientific
guideline. European Medicines Agency, 2024 draft.
https://www.ema.europa.eu/en/development-manufacture-oligonucleotides-scientific-guideline
Draft guideline on quality aspects of mRNA vaccines.
European Medicines Agency, 2025.
https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-mrna-vaccines_en.pdf
MRESVIA. U.S. FDA, 2024. https://www.fda.gov/vaccines-blood-biologics/vaccines/mresvia
Kostaive. European Medicines Agency EPAR, 2025.
https://www.ema.europa.eu/en/medicines/human/EPAR/kostaive
Report on the Deliberation Results: Kostaive. PMDA, 2023.
https://www.pmda.go.jp/files/000269813.pdf
Novel Drug Approvals for 2025. U.S. FDA, 2026.
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
FDA Approves Novel Treatment for Hemophilia A or B, with or
without Factor Inhibitors. U.S. FDA, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-hemophilia-or-b-or-without-factor-inhibitors
Drug Trials Snapshots: DAWNZERA. U.S. FDA, 2025.
https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-dawnzera
FDA approves drug to reduce triglycerides in adults with
familial chylomicronemia syndrome. U.S. FDA, 2025.
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-reduce-triglycerides-adults-familial-chylomicronemia-syndrome
FDA approves add-on therapy to lower cholesterol among
certain high-risk adults. U.S. FDA, 2021.
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults
FDA approves treatment of amyotrophic lateral sclerosis
associated with a mutation in the SOD1 gene. U.S. FDA, 2023.
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene
Drug Trials Snapshots: IZERVAY. U.S. FDA, 2023.
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-izervay
FDA Approves Required Updated Warning in Labeling of mRNA
COVID-19 Vaccines Regarding Myocarditis and Pericarditis Following Vaccination.
U.S. FDA, 2025. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-approves-required-updated-warning-labeling-mrna-covid-19-vaccines-regarding-myocarditis-and?hl=en-US
In-depth reviews
Advances in oligonucleotide drug delivery. Nature Reviews
Drug Discovery, 2020. https://www.nature.com/articles/s41573-020-0075-7
Drug delivery systems for RNA therapeutics. Nature Reviews
Genetics, 2022. https://www.nature.com/articles/s41576-021-00439-4
Chemistry, structure, and function of approved
oligonucleotide therapeutics. Nucleic Acids Research, 2023.
https://academic.oup.com/nar/article/51/6/2529/7070965
Advancements in clinical RNA therapeutics: Present
developments and prospective outlooks. Cell Reports Medicine, 2024.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11148805/
What will it take to get miRNA therapies to market?. Nature
Biotechnology, 2024. https://www.nature.com/articles/s41587-024-02480-0
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
New England Journal of Medicine, 2022.
https://www.nejm.org/doi/full/10.1056/NEJMoa2204705
Plozasiran for Managing Persistent Chylomicronemia and
Pancreatitis Risk. New England Journal of Medicine, 2024.
https://www.nejm.org/doi/10.1056/NEJMoa2409368
Delivery, manufacturing, and platform technologies
High-throughput barcoding of nanoparticles identifies
cationic, degradable lipid-like materials for mRNA delivery to the lungs in
female preclinical models. Nature Communications, 2024.
https://www.nature.com/articles/s41467-024-45422-9
Artificial intelligence-guided design of lipid nanoparticles
for pulmonary gene therapy. Nature Biotechnology, 2025.
https://www.nature.com/articles/s41587-024-02490-y
Template-independent enzymatic synthesis of RNA
oligonucleotides. Nature Biotechnology, 2025.
https://www.nature.com/articles/s41587-024-02244-w
Nanoparticulate delivery and targeting of RNA to the brain.
Biochimica et Biophysica Acta - Cancer Reviews, 2025.
https://www.sciencedirect.com/science/article/pii/S0304419X25002227
A First-in-Human Clinical Trial to Evaluate the Safety,
Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients
with Mecp2 Duplication Syndrome. ClinicalTrials.gov, 2024-2026.
https://clinicaltrials.gov/study/NCT06615206
Business, policy, and access
Moderna and Merck Present 5-Year Data for Intismeran
Autogene in Combination With KEYTRUDA in Patients With High-Risk Stage III/IV
Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting. Merck,
2026. https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/
Lilly to acquire Orna Therapeutics to advance cell
therapies. Eli Lilly and Company, 2026.
https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies
Novo Nordisk to acquire Cardior Pharmaceuticals and
strengthen pipeline in cardiovascular disease. Novo Nordisk and Cardior
Pharmaceuticals, 2024.
https://cardior.de/wp-content/uploads/2024/03/PR240325_Cardior_Final.pdf
Press Release by the Korea Disease Control and Prevention
Agency: mRNA Vaccine Development Support Project. KDCA, 2025.
https://www.kdca.go.kr/bbs/eng/189/225954/download.do
Call for applications - 2025 Hands-on training for mRNA
vaccine manufacturing organised by the Global Training Hub for Biomanufacturing
in the Republic of Korea, supported by the World Health Organization. World
Health Organization, 2025.
https://www.who.int/news-room/articles-detail/call-for-applications-2025-hands-on-training-for-mrna-vaccine-manufacturing-organised-by-the-global-training-hub-for-biomanufacturing-in-the-republic-of-korea--supported-by-the-world-health-organization
No comments:
Post a Comment